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tributing to improvements in the care of patients with
AAAs. This article describes the operational guidelines for
the Registry that permit accomplishment of these goals and
current efforts to develop a commercial patient surveillance
mechanism that is adaptable to all clinical practice models.
VALUE OF REGISTRY DATA
The Lifeline Registry provides cost-efficient complete
prospective data on these new devices given the limited
nature of the Phase II and Phase III clinical trials (concur-
rent, not randomized controls and short follow-up). The
Registry is available to manufacturers to use for addressing
postapproval requirements for the FDA. When manufac-
turers choose to participate in the Registry, all consented
patients are automatically entered into the Registry, and
input of data for these patients is mandatory for the com-
panies to address FDA requirements. Manufacturers are
not required to participate in the Registry. The data col-
lected will generate information to improve device design,
patient selection, and patient management.
THE LIFELINE REGISTRY MISSION
The Lifeline Registry was established before any EGs
were given marketing approval, with the express intent of
instituting a standard protocol applicable to multiple
patient populations. By pooling data from all EG manu-
facturers, the Registry’s objectives are to (1) evaluate and
report on the long-term survival of EG patients with vary-
ing risk profiles, (2) monitor long-term EG device perfor-
mance for safety, and (3) analyze factors in graft design or
patient management strategies that identify potential
improvements in devices or clinical care. The results will
In the last half of the 1990s, there was expanding
interest in the use of endovascular grafts (EGs) for repair-
ing some of the 200,000 life-threatening abdominal aor-
tic aneurysms (AAAs) diagnosed each year in the United
States. There has been rapid evolution of the field, and
several trials approved by the US Food and Drug
Administration (FDA) have been initiated to evaluate
EGs. In late 1999, two EG devices from two different
medical device companies received marketing approval
from the FDA, making the devices commercially available
to additional clinicians and institutions after training and
demonstrated surgical success.
In establishing the Lifeline Registry, a unique collabo-
ration was formed between the clinicians, professional soci-
eties, industry, and US governmental agencies (FDA, the
Center for Medicare and Medicaid Services [CMS, for-
merly the Health Care Financing Administration], and the
National Heart, Lung and Blood Institute [NHLBI]). The
Registry will provide an opportunity to define appropriate
patients for endograft therapy and to evaluate long-term
device performance and patient outcome, thereby con-
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Purpose: The purpose of this study is to collect and analyze long-term outcome data on the safety and effectiveness of
endovascular grafts used in abdominal aortic aneurysm repair in the United States and Canada. We aimed to help define
appropriate patients for endograft therapy and to evaluate long-term device performance and patient outcome, thereby
contributing to improving the care of patients with abdominal aortic aneurysms.
Methods: Data entered in the Registry include the electronic data collected under the endovascular graft manufacturers’
clinical trials, prospective follow-up data of patients enrolled in these trials, both from the clinical centers and from
interviews conducted at New England Research Institutes, and explant data, obtained primarily from analyses con-
ducted by the Registry central pathology laboratory.
Scope: The Registry records and analyzes the long-term follow-up data of patients in the clinical trials that lead to
devices approved by the Food and Drug Administration. The Registry has also launched a feasibility study to expand
the Registry to include patients receiving commercial endovascular grafts, the devices available following Food and
Drug Administration marketing approval. (J Vasc Surg 2001;34:1139-46.)
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be made available to the collaborators and to the medical
community at large.
REGISTRY ORGANIZATION, FUNDING, AND
DECISION-MAKING
Steering Committee. The Lifeline Registry’s Steering
Committee first convened on November 20, 1998. The
Steering Committee (Appendix 1) is the central and ultimate
decision-making body of the Registry, establishing policy for
the collaborative. The Steering Committee is advised by, and
has, to date, met jointly with, the Registry’s Industry
Advisory Committee (Appendix 2), currently composed of
representatives of all companies with EG devices and con-
ducting (or planning to conduct) research on these devices
in the United States. An Executive Committee corresponds
weekly to ensure smooth, timely execution of the Data
Center and Registry work between Steering Committee
semiannual meetings and interim conference calls.
The membership of the Registry Steering Committee, its
policy-making body, has been carefully constructed to ensure
independence in decision-making and appropriate expertise. 
There are seven voting positions (Table I). Single
votes reside with each of the following: the President of
Lifeline Foundation; the Technology Assessment and
Clinical Trials Committee, Lifeline Foundation (three
clinicians, one vote); the Chair of the Technology
Assessment Committee (formerly the Committee on
Endovascular Issues of the Joint Vascular Societies, Society
for Vascular Surgery/American Association for Vascular
Surgery [SVS/AAVS]); the Chair of the Registry’s
Clinical Adverse Endpoints Committee; the Chair of the
Registry’s Device Endpoints and Explant Committee; and
the Registry Data Center (New England Research
Institutes). The Steering Committee Chair, who is the
Chair of the Lifeline Technology Assessment and Clinical
Trials Committee, votes only to break a tie.
There are also seven nonvoting (ex officio) members
who provide expertise and continuity and participate in all
Steering Committee discussions. They include representa-
tives from the FDA, the CMS, and the NHLBI, Past Chair
of the Lifeline Registry Steering Committee (currently
vacant), Past Chair of the Committee on Endovascular
Issues of the SVS/AAVS, Past Chair of the Registry’s
Clinical Adverse Endpoints Committee (currently vacant),
and Past Chair of the Registry’s Device Endpoints and
Explant Committee (currently vacant).
No representatives of the EG industry are on the
Steering Committee. Rather, the device manufacturers are
organized into the separately constituted Industry Advisory
Committee. Meetings of the Registry Steering Committee
are usually held jointly with the Industry Advisory
Committee to facilitate discussion.
The following working committees report to the
Steering Committee:
• The Clinical Adverse Events Committee (Appendix 3)
has developed the Registry clinical data collection pro-
tocol.
• The Device Endpoint and Explant Committee (Appen-
dix 4) has established a centralized, standard system for
identifying and completing EG explants (obtained at
surgical conversion to open repair or at autopsy) and for
analyzing the resulting tissue and EG material.
• The Endpoint Adjudication and Publication Commit-
tees manage critical steps in review of Registry patient
and device outcome data and dissemination of Registry
findings.
Funding mechanism. The Registry is funded by the
Lifeline Foundation and EG manufacturers with a com-
mercial device and/or conducting or planning United
States–based clinical trials. Initial and continued support
from NHLBI may result in partial funding of appropriate,
scientific activities once the postmarketing surveillance
(PMS) is established.
Stakeholders (collaborating constituencies). The
four key stakeholders interested in both the immediate
and long-term effectiveness of this new technology collab-
orate as members of the Lifeline Registry of Endovascular
Aneurysm Repair. They include the following: clinicians
who are implanting the new EGs; companies in the med-
ical device industry that support the development and
testing of EGs; specialty societies that develop and pro-
mulgate standards of care for patients receiving EGs; and
government agencies that are responsible for regulating,
researching, and reimbursing device costs. This Registry
has partnered with an independent organization not affil-
iated with any other stakeholder (New England Research
Institutes, Inc), to serve as the Data Center, which col-
lects, manages, and analyzes the Registry data on the long-
term effectiveness of EGs.
METHODS
Standardized reporting. Collaboration of clinician,
industrial, and governmental members of the Registry have
developed standard case report forms (CRFs) for data col-
lection. A similar effort produced an explant protocol with
standards for the procurement and physical, pathologic,
and imaging examination of EG explants. These standard
protocols fulfill the needs of all collaborators and provide
cost efficiency in industry protocol development and clar-
ity and consistency across manufacturers and clinicians pro-
viding data. Manufacturers who initiated clinical trials
before development of the Lifeline protocol have trans-
ferred data to the Registry. Manufacturers initiating clinical
trials after development of the Registry protocol are using
CRFs compatible with the Registry database.
Currently the Lifeline Registry patient population
comprises patients who received their EG during a Phase
II or Phase III clinical trial and whose data were submit-
ted to the FDA as part of a premarketing approval (PMA)
application. These patients are being followed for 5 years
from the implantation of the EG device, based on agree-
ments between the manufacturers with PMA and the
FDA. Consent was obtained a second time from all
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patients to permit follow-up as part of the Registry.
Manufacturers still planning or implementing clinical trials
under investigational device exemptions are encouraged to
adopt the Registry protocol for data collection (surgical
outcome, status of patient, aneurysm, and device postsur-
gically and at follow-up examinations, adverse events, and
explant), so that once PMA is obtained, these data can be
readily merged into the Registry for continuing follow-up
and aggregate analyses.
PMA patient follow-up. Two manufacturers—
Medtronic AVE and Guidant Endovascular Solutions—
received PMA for their endovascular devices to repair AAA
in September 1999. To make their devices commercially
available to newly trained clinicians, the manufacturers
agreed to follow the patients, whose data were submitted
to the FDA to obtain the PMA, for at least 5 years from
the date of EG implantation. Data on patients receiving
these investigational devices, including presurgical assess-
ments, data on the initial surgery, and short-term follow-
up data on medical and device complications, have been
shared with the Registry. The existing databases are pro-
vided by the manufacturers electronically and are copied
to the Registry. After the “mapping” of the manufacturer
data elements into the Registry data points and external
validation of this process, the data are accepted into the
Registry database. Prospective patient follow-up ensues.
Manufacturers and the participating clinical centers jointly
choose the mode of follow-up, using the Registry CRFs
and protocol to provide 5-year follow-up data prospec-
tively to the Registry. Long-term follow-up of the clinical
trial patients is mandatory; the manufacturers have com-
mitted to such data collection in their PMA applications.
Information collected on patients during the clinical
trial, before submission of the PMA application, are pro-
vided electronically to the Registry. Trial data include
presurgical medical assessment, aneurysm evaluation,
indications for surgery, operative results, and postsurgical
patient examinations and imaging before discharge, 1 to
3 months later, at 6 months and 12 months postopera-
tively, and annually thereafter. Data from interim visits
between scheduled follow-ups, usually indicated by med-
ical symptoms or events, are also obtained and down-
loaded to the Registry. Data being collected prospectively
under the Registry protocol at each annual visit to the
implanting surgeon focus on (1) the results of the physi-
cal examination; (2) the aneurysm measurements from
the annual imaging; and (3) characterization of the status
of the following:
• the patient (new vascular and nonvascular illnesses);
• the aneurysm (measurements by appropriate image,
exclusion by EG, endoleaks, enlargement, and rup-
ture); and
• the device (intact and patent, migration, change in
alignment, loss of device integrity, and obstruction).
Appendix 5 is the one-page CRF and accompanying
definitions that are collected by the clinical centers pro-
viding prospective data directly to the Registry at each
annual and any interim follow-up visits; if the patient is
not well, if the aneurysm is not primarily excluded, or if
the device is not intact and patent, additional information
and details are recorded in a standard fashion on addi-
tional CRFs. Table II lists the important data elements
being monitored during long-term follow-up of EG
patient outcome and device effectiveness.
Data on demographics, risk factors, physical measure-
ments, and adverse events such as endoleaks, aneurysm
enlargement, prosthesis migration, and device obstruction
have been analyzed and can be seen in the upcoming pub-
lication “Lifeline Registry Report No. 1.” Provisions for
periodic, regular reporting and publication are discussed
below. Some data on open surgical control patients are
available to the Registry; however, 5-year follow-up of
these patients’ outcomes was not uniformly required in
the PMAs of the two EG devices on the market.
Data on all patients receiving EGs during a clinical
trial in the United States are submitted to the FDA in a
PMA application; however, there are generally several dif-
ferent study phases and/or study arms. Devices are modi-
fied, devices are withdrawn from further development,
and/or manufacturers change business plans during the
study. Therefore, not all clinical trial patient populations
are required to be followed to address FDA postmarketing
requirements, and there are some patients who are being
followed in the registry whose data were not used to
Table I. Membership of Lifeline Registry Steering Committee
Voting members Nonvoting members
President, Lifeline Foundation
Technology Assessment and Clinical Trials Committee, Lifeline 
Foundation
Chair, Committee on Endovascular Issues, SVS/AAVS
Chair, Clinical Adverse Endpoints Committee, Lifeline Registry
Chair, Device Endpoints and Explant Committee, Lifeline 
Registry
Data Center, New England Research Institutes, Inc
Chair, Technology Assessment and Clinical Trials Committee, 
Lifeline Foundation
Office of Device Evaluation, Center for Devices and Radiological
Health, FDA
Vascular Biology Research Program, National Heart, Lung and
Blood Institute, National Institutes of Health
Coverage and Analysis Group, Center for Medicare and  
Medicaid Services 
Past Chair, Lifeline Registry Steering Committee
Past Chair, Committee on Endovascular Issues, SVS/AAVS
Past Chair, Clinical Adverse Endpoints Committee, Lifeline 
Registry
Past Chair, Device Endpoints and Explant Committee, Lifeline 
Registry
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specifically support safety and effectiveness in a PMA
application. The Registry expects that some of these
extant, yet limited, EG databases will be contributed to
the Registry, with appropriate data elements mapped into
the Registry database, prospective data as accumulated
shared with the Registry, and the resulting data analyzed
with the Guidant and Medtronic AVE data to the degree
deemed statistically allowable.
Commercial EG surveillance. Surveillance of patients
after deployment of FDA-approved EG devices is an area
requiring a focused approach to ensure cost-effective, reli-
able data acquisition and retrieval. A Lifeline Registry–spon-
sored study funded by Medtronic AVE is assessing the
feasibility of an online registry in five diverse clinical centers
implanting the commercial EGs to address this issue. The
data collected are similar to those in the PMA protocol but
not as extensive. An additional feature of the PMS study that
is being tested is the inclusion of imaging stills in the
Registry database, available online for clinician review at sub-
sequent patient visits. The feasibility study includes data col-
lected on consecutively enrolled patients receiving the
Medtronic AVE commercially-available EG device at five US
sites. All patients provide Institutional Review Board–
approved consent. It is expected that the Lifeline Registry
will make the PMS registry available to additional clinicians,
institutions, and manufacturers, if the concept meets the rec-
ognized clinical need.
Publication of Registry data. The Registry Publi-
cations Committee will approve manuscripts to be submit-
ted to peer-reviewed journals using the aggregate Registry
database of patients from multiple manufacturers. The
Registry wants to circulate data from its database, and has
been invited by the Journal of Vascular Surgery to regularly
submit data summaries for publication; the data elements to
be reported are being determined by the Registry Clinical
Adverse Events Committee.
The data availability policy governing access to and
responsibility for provision of data was established early and
codified in one written document, approved by the Steering
Committee and the Industry Advisory Committee, in
1999. The policy currently references data arising from
Phase II and Phase III studies, conducted under IDEs, and
is a key element in this electronic data environment with
Internet data entry and access; each manufacturer has access
to data and standard reports on its IDE patients, and simi-
larly each clinical center and clinician has access to data and
standard reports on patients who have undergone surgery
at that institution under an IDE. Reports are produced
from the Registry pooled database by the Data Center, on
behalf of the Steering Committee, that allow centers and
manufacturers to compare their performance with the
aggregate, and allow analysis by all collaborators. An impor-
tant element of the current policy is that reports or articles
using aggregate data that do not compare or identify indi-
vidual devices will be published without requiring manufac-
turer approval. Given that the Registry currently includes
only patients enrolled in Phase II and Phase III trials under
IDEs, a second element of the policy stipulates, appropri-
ately, that individual devices cannot be identified or com-
pared in published analyses without prior approval by the
Table II. Lifeline Registry protocol for clinical trial EG patients, data elements collected at follow-up visits
Clinical measurements
Blood pressure
Ankle-brachial index
Aneurysm measurements
Maximum aneurysm diameter
Proximal aortic neck, minimum diameter
Distal aortic neck, minimum diameter (tube grafts only)
Patient status
Alive or dead
Vascular-related or nonvascular-related problems
Hospitalizations since last visit
Antiplatelet or anticoagulant therapy
Presence of new or worsening condition
Lower-extremity arterial obstruction
Hypertension
Renal disease, renal failure
Renal artery obstruction
Ischemic bowel
Aortoenteric fistula
Pseudoaneurysm
Smoking status
Cardiac disease
Pulmonary disease
Cerebrovascular disease
Diabetes
Cancer
Liver disease
Coagulopathy
Aneurysm status (characterized as one or more of the following 
since last visit)
Excluded, primary success
Excluded, secondary success
Endoleak, new or continuing (source)
Enlarged (increase of ≥5 mm)
Ruptured
Intervention to correct a problem with aneurysm, since last 
visit (type, date, and outcome) 
Device status (characterized as one or more of the following since 
last visit)
Primarily intact and patent
Secondarily intact and patent
Prosthesis migration (components, cause, associated endoleak)
Change in graft alignment (type, associated endoleak, associ-
ated obstruction)
Loss of device integrity (attachment system fracture; support 
frame fracture; graft wall defect, tear, or disruption; graft 
material dilatation; modular disconnection, associated 
endoleak; migration; or obstruction)
Obstruction, limb or body (cause, severity, site)
Device-related renal artery obstruction
Device-related visceral artery obstruction
Device-related aortoenteric fistula
Device-related pseudoaneurysm
Graft infection
Intervention to correct a problem with EG device since last 
visit (type, date, and outcome)
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device manufacturer(s) involved. With the broadening of
the Registry to include commercially available devices, this
second component of the Data Availability Policy will be
reassessed.
With the PMAs granted by the FDA requiring 5-year
follow-up of the clinical trial patients of these two manu-
facturers, the Lifeline Registry has been able to collect
comprehensive and accurate follow-up data that overcome
the voluntary nature of data collection that can pose data
quality issues in other registries.
Additional Registry activities. The Registry is dis-
cussing use of its Internet-based data collection system by
other registries, eg, a consortium of Canadian endovascular
specialists and the Veterans Affairs Randomized
Endovascular Graft study. The Registry also plans to include
patients receiving EGs to repair thoracic aneurysms.
Successful completion of a feasibility study on PMS of
patients receiving commercially available EGs should herald
the expansion of the Registry to PMS data collection.
Although the PMS expansion of the Registry will be volun-
tary, every attempt will be made to maintain a complete
Registry, working with the manufacturers to identify and
contact clinical centers that have been certified for device
implant. The Device Endpoint and Explant Committee is
also working to increase the number of EG explants
obtained and analyzed by making available a standardized
protocol giving guidance for performing EG explants, a cen-
tral laboratory to conduct pathologic analysis of removed
graft/tissue specimens, and an international committee of
cardiovascular device experts to evaluate all results.
ONGOING CHALLENGES
The operational challenges faced by the Registry to date
have centered on the main tenet of the Registry, the sharing
of data on manufacturers’ clinical trial patients. When the
Registry began, individual manufacturers were in different
stages of development, and the Registry and manufacturers
have had to construct separate but appropriate interfaces for
manufacturers at various stages of clinical trial and protocol
development. Clinical knowledge and research questions
surrounding this new technology have changed and grown
considerably in the last 2 years, challenging the Registry pro-
tocol to be dynamic, responsive, and current.
The critical operational challenge in a collaboration of
such diverse organizations is that of conflict resolution.
Structural solutions are necessary to enable the setting of
policy and the execution of decisions. The Lifeline
Registry has been successful by relying on consensus
building among all stakeholders, using the Steering and
Industry Advisory Committees as the foci of discussion
and vehicles for conflict resolution. In addition, joint
meetings of these two committees have facilitated decisions
and reduced conflict, because all stakeholders are repre-
sented. The Steering Committee is clearly designated as the
decision-making body, whereas the Industry Advisory
Committee is advisory and the Executive Committee and
Data Center are the implementation arms. Key policies have
been established and are continuously referred to as guide-
lines. The written Conflict of Interest policy is reviewed at
each meeting. The Publications policy is being developed,
with the Journal of Vascular Surgery being designated as the
primary vehicle for regular reporting to the broader medical
community. In addition to general confidentiality policy
and rules on patient confidentiality, specific documents have
been developed addressing the interfaces between industry
and the Data Center and industry and the Device
Endpoints and Explant Committee.
SUMMARY
This Registry provides an important prototype for sim-
ilar consortia between industry and clinical societies that
facilitate and fund cost-efficient databases to monitor the
long-term safety and effectiveness of medical devices. The
most important features of this Registry are the following:
patient follow-up is mandatory, not voluntary, with full par-
ticipation of all EG manufacturers, all clinical centers, and
all patients that meet Registry definitions for inclusion, and
the Registry offers an effective vehicle for collecting data for
this mandated follow-up; the conduct of the Registry is
independent of the manufacturers; and the manufacturers
who fund the Registry have advisory input and benefit
directly from the efficiencies provided by the collaboration.
The Registry protocol is accepted by the FDA and the CMS
(formerly the Health Care Financing Administration).
Funding of procedures is facilitated, and manufacturers
have access not only to their own data, but to reports of
aggregate device experience that can be used comparatively.
The Registry thus provides cost-efficiency in protocol
development and FDA submissions and required reporting.
Submitted May 17, 2001; accepted Aug 30, 2001.
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Appendix 2. Companies represented on the Industry
Advisory Committee
C. R. Bard, Inc
Boston Scientific Corporation
Cook Incorporated
Cordis Corporation
Edwards Lifesciences LLC
Endologix, Inc
W. L. Gore & Associates
Guidant Corporation
Medtronic AVE
Sulzer Vascutek, Ltd
Appendix 3. Members of the Lifeline Registry Clinical
Adverse Events Committee
Member Affiliation
James DeWeese, MD Chair, Clinical Adverse Events 
Committee
Gary M. Ansel, MD American College of Cardiology
Victor M. Bernhard, MD SVS/AAVS
Richard M. Green, MD SVS/AAVS
Barry T. Katzen, MD Society for Cardiovascular and 
Interventional Radiology
Rodney A. White, MD SVS/AAVS
Christopher K. Zarins, MD SVS/AAVS
Appendix 4. Members of the Registry Device
Endpoints and Explant Committee
Member Affiliation
Seymour Glagov, MD Chair
James F. McKinsey, MD Co-Chair
Jagdish W. Butany, MBBS, MS, FRCPC
Frederick J. Schoen, MD, PhD
Renu Virmani, MD
Appendix 1. Members of the Lifeline Registry Steering Committee
Member Affiliation
Rodney A. White, MD Chair, Lifeline Registry Steering Committee
Dorothy Abel FDA
Jack L. Cronenwett, MD Technology Assessment and Clinical Trials Committee, Lifeline Foundation
James A. DeWeese, MD Chair, Registry Clinical Adverse Events Committee
Thomas J. Fogarty, MD Technology Assessment and Clinical Trials Committee, Lifeline Foundation
Seymour Glagov, MD Chair, Registry Device Endpoints and Explant Committee
David Gordon, MD NHLBI
Kim J. Hodgson, MD Technology Assessment and Clinical Trials Committee, Lifeline Foundation
John A. Mannick, MD President, Lifeline Foundation
Sonja McKinlay, PhD Principal Investigator, Registry Data Center, New England Research Institutes
Gregorio A. Sicard, MD Chair, Technology Assessment Committee
Kenneth Simon, MD, MBA CMS
Christopher K. Zarins, MD Past Chair, Committee on Endovascular Issues of SVS/AAVS
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Appendix 5. Lifeline Registry of Endovascular Aneurysm Repair, form F1, follow-up.
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